Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
about
Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesEpithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspectsProphylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells.B cell TLRs and induction of immunoglobulin class-switch DNA recombination.Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environmentEffects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer.Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cellsCpG expedites regression of local and systemic tumors when combined with activatable nanodelivery.Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.Toll-like receptors and their role in carcinogenesis and anti-tumor treatment.Significance of toll-like receptors expression in tumor growth and spreading: a short reviewTherapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.Immunoregulation of GVHD by triggering the innate immune system with CpG.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis.LPS induced miR-181a promotes pancreatic cancer cell migration via targeting PTEN and MAP2K4.A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses.Prizes and parasites: incentive models for addressing Chagas disease.Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.Treatment of allergic rhinitis with CpG oligodeoxynucleotides alleviates the lower airway outcomes of combined allergic rhinitis and asthma syndrome via a mechanism that possibly involves in TSLP.
P2860
Q24624348-14379BDE-948B-481D-9F5D-96A4A495016CQ27025290-449311ED-3DBC-4039-B420-EC486E623FDAQ33676552-BEE9BC83-3378-4546-801E-FA54BA845638Q33806328-550ADAB8-14DF-47CC-9844-80EC55A8A805Q33893517-07E6DEBD-5CE3-411A-88CA-C2386EE9323BQ34242591-5D222C0F-1C6B-4ABA-8AC8-4B682AAFB34DQ34671033-E7897D29-E921-4413-AB4F-DF46EBA489F4Q35740077-92E68E6E-B4C1-4697-AE5E-60FC27936DD4Q36395752-C200AD60-6EA1-4543-8D38-DE5000486AEDQ36527473-A5F94C97-C99B-45A8-A510-6FE9B1438AE9Q37351412-B222C741-3BA8-493C-989B-F1F4D1A9BA38Q37354939-35261750-C1B9-44D9-B5D6-649AC3326CAFQ37421540-387D6327-8832-4B1F-A642-1CD88C5CB712Q37497786-43CF8472-407A-4EB8-912E-C763C77F2973Q37810081-5334A46F-922D-4D71-BB9F-96F7C8F3AEBDQ37812128-C2F56220-A79F-4238-8B2A-62111DFB6B06Q38085679-BCF772CB-A015-4902-B34C-0672642D7E38Q38290398-98359547-444B-4A5C-8938-3EF7D670D24DQ39023380-3AB6BC7E-D625-494B-9758-0B5551945F37Q39657008-F18E2AB2-6F1C-4091-96B6-B073C9EC2423Q47905175-81A2C71D-481F-4A74-8F6D-2B5A1D183FA8Q49997050-E20902A6-0ED3-4266-B734-78683BF75EE4Q51468541-DB4D1844-8136-437E-A8F4-3AED2BCD6891
P2860
Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic applications of sy ...... gonists for immune modulation.
@en
Therapeutic applications of sy ...... gonists for immune modulation.
@nl
type
label
Therapeutic applications of sy ...... gonists for immune modulation.
@en
Therapeutic applications of sy ...... gonists for immune modulation.
@nl
prefLabel
Therapeutic applications of sy ...... gonists for immune modulation.
@en
Therapeutic applications of sy ...... gonists for immune modulation.
@nl
P2860
P1433
P1476
Therapeutic applications of sy ...... gonists for immune modulation.
@en
P2093
Jörg Vollmer
Marion Jurk
P2860
P304
P356
10.2165/00063030-200721060-00006
P577
2007-01-01T00:00:00Z
P6179
1022633898